BNA Annual General Meeting 2025
1st April 2025
The successful candidate will be part of a team generating viral vector gene therapy reagents aimed at treating amyotrophic lateral sclerosis (ALS) and fronto-temporal dementia (FTD) on a commercially funded project. The aim of the project is to optimise the dose and delivery of gene supplement and knock-down vectors in cellular and animal models of disease as proof of concept and efficacy for potential clinical application. Working with Professor Shaw and Dr Youn Bok Lee they will join a team of Post-doctoral Scientists, Technicians and PhD students analysing cells and tissues transduced with plasmid and vector constructs and quantify the effects on target gene expression. They will be responsible for generating novel plasmid and Adeno Associated Viral (AAV) vectors and testing their potency in cellular and animal models. Essential molecular and cellular biology skills include: gene cloning, purifying plasmid DNA, cell culture, transfection and the quantification of vector genomes, expressed mRNA and protein. All experiments will be undertaken at a very high standard and all data treated with complete confidentiality. This post offers an exciting and rewarding opportunity to pursue a career in Gene Therapy in Academia or Industry.
This post will be offered on an a fixed-term contract to December 31st 2022.
This is a full-time post - 100% full time equivalent.